Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma

World Journal of Surgical Oncology

Jian Zhang²  Xiuli Jiang¹  Jianli Zhang² 

[1] Department of Nutrition, The Affiliated Hospital of Qingdao University, 59 Haier Road, Qingdao 266000, Shandong Province, China;Department of General Surgery, The Affiliated Hospital of Qingdao University, 59 Haier Road, Qingdao 266000, Shandong Province, China

关键词: XB130;    Prognosis;    Immunohistochemistry;    Pancreatic ductal adenocarcinoma;   

Others  :  820290
DOI  :  10.1186/1477-7819-12-49

 received in 2013-12-14, accepted in 2014-02-19,  发布年份 2014

【 摘 要 】

Background

XB130 is a newly discovered adaptor protein for intracellular signal transduction; it is involved in gene regulation, cell proliferation, cell survival, cell migration, and tumorigenesis. However, its expression and role in pancreatic ductal adenocarcinoma (PDAC) have not been investigated. The present study was designed to clarify the prognostic significance of XB130 expression in PDAC.

Methods

A total of 76 consecutive patients with surgically resected PDAC were retrospectively reviewed. XB130 expression was detected by immunohistochemical analysis on the paraffin-embedded tumour sections. Correlation between the expression of XB130 and clinicopathological parameters was analyzed.

Results

XB130 expression was significantly upregulated in PDAC(56.5%, 43/76) compared to normal pancreas (0%, 0/15; P < 0.05). Increased XB130 expression was correlated with lymph node metastasis (P = 0.017), distant metastasis (P = 0.0024), high tumour-node-metastasis (TNM) stage (P =0.001), and high tumour grade (P = 0.013). The survival of 43 patients with high XB130 expression was significantly worse than that of the 33 patients with low XB130 expression (P = 0.001). Univariate analysis showed that high XB130 expression (P = 0.0045), tumour size (P = 0.024), distant metastasis (P = 0.003), TNM stage (P = 0.002) and lymphatic metastasis (P = 0.016) were independent prognostic factors of postoperative survival. Multivariate analysis using the Cox proportional hazards model showed that high XB130 expression and distant metastasis (P = 0.0239) were significant independent risk factors.

Conclusions

XB130 was overexpressed in the PDAC. XB130 is a promising pathological marker for the prediction of outcome in patients with PDAC.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Geer RJ, Brennan MF: Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993, 165:68-72.
• [2]Cameron JL, Riall TS, Coleman J, Belcher KA: One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006, 244:10-15.
• [3]Kleeff J, Michalski C, Friess H, Buchler MW: Pancreatic ductal adenocarcinoma: from bench to 5-year survival. Pancreas 2006, 33:111-118.
• [4]Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic ductal adenocarcinoma stem cells. Cancer Res 2007, 67:1030-1037.
• [5]Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K: Prognostic factors after resection of pancreatic ductal adenocarcinoma. World J Surg 2009, 33:104-110.
• [6]Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB: Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J 2013, 54:643-649.
• [7]Hilgers W, Kern SE: Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer 1999, 26:1-12.
• [8]Shiozaki A, Liu M: Roles of XB130, a novel adaptor protein, in cancer. J Clin Bioinforma 2011, 1:10. BioMed Central Full Text
• [9]Xu J, Bai XH, Lodyga M, Han B, Xiao H: XB130, a novel adaptor protein for signal transduction. J Biol Chem 2007, 282:16401-16412.
• [10]Shiozaki A, Lodyga M, Bai XH, Nadesalingam J, Oyaizu T: XB130, a novel adaptor protein, promotes thyroid tumor growth. Am J Pathol 2011, 178:391-401.
• [11]Shiozaki A, Kosuga T, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Iitaka D, Nakashima S, Shimizu H, Ishimoto T, Kitagawa M, Nakou Y, Kishimoto M, Liu M, Otsuji E: XB130 as an independent prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol 2013, 20:3140-3150.
• [12]Zuo Q, Huang H, Shi M, Zhang F, Sun J, Bin J, Liao Y, Liao W: Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. Anat Rec (Hoboken) 2012, 295:423-431.
• [13]Shi M, Huang W, Lin L, Zheng D, Zuo Q, Wang L, Wang N, Wu Y, Liao Y, Liao W: Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer. PLoS One 2012, 7:e41660.
• [14]Sobin LH, Gospodarowicz MK, Ch W: International Union Against Cancer (UICC) TNM Classification of Malignant Tumours. 7th edition. Oxford, UK: Wiley-Blackwell; 2009.
• [15]Sobin LH, Wittekind CH: TNM Classification of Malignant Tumours. 6th edition. New York: John Wiley & Sons; 2002:93-96.
• [16]Mukaiya M, Hirata K, Satoh T: Lack of survival benefit of extended lymph node dissection for ductal adenocarcinoma of the head of the pancreas: retrospective multi-institutional analysis in Japan. World J Surg 1998, 22:248-252.
• [17]Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP: Molecular prognostic markers in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Surg 2002, 9:1-11.
• [18]Ansari D, Rosendahl A, Elebro J, Andersson R: Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic ductal adenocarcinoma. Br J Surg 2011, 98:1041-1055.
• [19]Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnel MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic Experience (1975-2005). J Clin Oncol 2008, 26:3511-3516.